Clinical Trials
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In...
February 05, 2026 | News
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone paymen...
February 05, 2026 | News
SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million up...
February 04, 2026 | News
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...
February 03, 2026 | News
MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant...
February 03, 2026 | News
Strategic expansion positions Singapore as a strategic arm for healthcare logistics in the APAC region. DHL Group invests €10 million in a new phar...
February 02, 2026 | News
Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre&...
February 02, 2026 | Expert Insight
In this BioPharma APAC interview, Dr Yun Yen, Program Committee Chair for the 2026 ASCO Breakthrough meeting, shares a candid translational...
February 02, 2026 | Expert Insight
Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic disea...
February 02, 2026 | News
The momentum is real—and so is the level of scrutiny. As more programs move beyond regional boundaries, expectations from global biopharma companies ...
February 02, 2026 | News | By Anil Kane, executive director, global head of technical and scientific affairs, Thermo Fisher Scientific
Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, announced co...
February 02, 2026 | News
Telix Pharmaceuticals Limited announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for ...
January 30, 2026 | News
SK bioscience announced the initiation of a global Phase 1/2 clinical trial in Australia for GBP511, a vaccine candidate targeting the sarbecovirus subgenu...
January 30, 2026 | News
Kazia Therapeutics provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemothe...
January 29, 2026 | News
Most Read
Bio Jobs
News